Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 open-label, multicenter, non-randomized study to evaluate the safety and
efficacy of oral pazopanib as neoadjuvant treatment for patients with stage 1A, 1B, IIA or
IIB (to T2) resectable Non-Small Cell Lung Cancer (NSCLC).